Woodford Investment Management Ltd grew its position in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 0.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 10,706,180 shares of the biopharmaceutical company’s stock after acquiring an additional 1,072 shares during the quarter. Theravance Biopharma comprises 15.7% of Woodford Investment Management Ltd’s portfolio, making the stock its 4th biggest position. Woodford Investment Management Ltd owned about 20.06% of Theravance Biopharma worth $426,531,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Theravance Biopharma by 1,494.3% during the first quarter. Ameritas Investment Partners Inc. now owns 3,635 shares of the biopharmaceutical company’s stock worth $133,000 after acquiring an additional 3,407 shares during the last quarter. Aperio Group LLC acquired a new stake in Theravance Biopharma during the second quarter worth about $205,000. BNP Paribas Arbitrage SA increased its stake in Theravance Biopharma by 570.7% during the second quarter. BNP Paribas Arbitrage SA now owns 5,151 shares of the biopharmaceutical company’s stock worth $205,000 after acquiring an additional 4,383 shares during the last quarter. Amalgamated Bank acquired a new stake in Theravance Biopharma during the second quarter worth about $214,000. Finally, Harvest Management LLC acquired a new stake in Theravance Biopharma during the first quarter worth about $228,000. Institutional investors own 84.84% of the company’s stock.

Several equities research analysts have commented on the company. Cantor Fitzgerald set a $55.00 price target on Theravance Biopharma and gave the stock a “buy” rating in a research note on Wednesday, August 16th. Evercore ISI assumed coverage on Theravance Biopharma in a research note on Wednesday, August 16th. They set an “outperform” rating and a $45.00 price target for the company. Zacks Investment Research upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday. ValuEngine upgraded Theravance Biopharma from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, BidaskClub lowered Theravance Biopharma from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. Theravance Biopharma has a consensus rating of “Hold” and a consensus price target of $41.86.

Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) traded up 0.66% during midday trading on Friday, hitting $33.72. The stock had a trading volume of 52,654 shares. Theravance Biopharma, Inc. has a 1-year low of $23.15 and a 1-year high of $43.44. The firm has a 50-day moving average price of $29.57 and a 200-day moving average price of $35.29. The firm’s market cap is $1.82 billion.

In other Theravance Biopharma news, EVP Bradford J. Shafer sold 14,670 shares of the firm’s stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $30.77, for a total transaction of $451,395.90. Following the transaction, the executive vice president now directly owns 134,327 shares in the company, valued at $4,133,241.79. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Rick E. Winningham bought 10,000 shares of the business’s stock in a transaction on Friday, August 11th. The shares were bought at an average price of $24.50 per share, for a total transaction of $245,000.00. Following the completion of the acquisition, the chief executive officer now owns 866,377 shares of the company’s stock, valued at $21,226,236.50. The disclosure for this purchase can be found here. Over the last 90 days, insiders have acquired 20,000 shares of company stock worth $494,300. Corporate insiders own 6.10% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was published by Daily Political and is the sole property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of U.S. and international copyright legislation. The legal version of this report can be read at https://www.dailypolitical.com/2017/09/22/woodford-investment-management-ltd-increases-holdings-in-theravance-biopharma-inc-tbph.html.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a biopharmaceutical company. The Company is engaged in creating medicines for patients suffering from serious illness. The Company operates in the segment of discovery (research), development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting.

Want to see what other hedge funds are holding TBPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Theravance Biopharma, Inc. (NASDAQ:TBPH).

Institutional Ownership by Quarter for Theravance Biopharma (NASDAQ:TBPH)

Receive News & Ratings for Theravance Biopharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theravance Biopharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.